Skip to main content
OpenTrials
Completed

NCT Number: NCT07504783

A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab

The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom (UK), France, Germany, Italy, Spain, China, Japan, and Brazil.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Behavior Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Health Behavior Immune System Diseases Nervous System Diseases Patient Satisfaction Personal Satisfaction Treatment Adherence and Compliance

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Novartis

Basel, CH-4056, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Physician inclusion criteria:

  • Physicians must be actively involved in the treatment/management of patients with MS
  • Consult with a minimum of 16 MS patients (>5 in Japan and China, >10 in Brazil) per month

Patient inclusion criteria:

Patients for whom physicians complete a Physician Completed Patient Record Form (PRF), and therefore are included in the pool of data for analysis, are based on the following criteria:

  • Patients who had a physician-made diagnosis of MS before or at the time of data collection
  • Patients must not currently be involved in a clinical trial
  • Patients ≥18 years old
  • For patients included in the ofatumumab sample, they must have been receiving ofatumumab for >12 months at the time of data collection

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Number and Percentage of Patients by Patient-reported Level of Satisfaction With Current MS Treatment

    Time frame: 1 Day

    Patient's level of satisfaction with current treatment categorized as follows:

    • Completely dissatisfied
    • Moderately dissatisfied
    • Neither dissatisfied nor satisfied
    • Moderately satisfied
    • Completely satisfied
    • Not on any current treatment for MS

  2. Number and Percentage of Patients by Patient-reported MS Status With Their Current Medication Compared to Previous Medication

    Time frame: 1 Day

    MS status, as reported by the patient, categorized as follows:

    • Very much better
    • Much better
    • A little better
    • No change
    • A little worse
    • Much worse
    • Very much worse
    • Don't know
    • No previous medication taken for MS

  3. Number and Percentage of Patients by Physician-reported Patient Response to Current MS Treatment

    Time frame: 1 Day

    How well the patient is responding to current treatment rated by the physician from 1 (very poorly) to 5 (very well).

  4. Number and Percentage of Patients by Physician-reported Level of Satisfaction With the Patient's Current MS Treatment

    Time frame: 1 Day

    Physician's level of satisfaction with patient's current treatment categorized as follows:

    • Completely dissatisfied
    • Moderately dissatisfied
    • Neither dissatisfied nor satisfied
    • Moderately satisfied
    • Satisfied
    • Completely satisfied

  5. Number and Percentage of Patients Adherent to Current MS Treatment as Reported by the Physician

    Time frame: 1 Day

    Adherence, as reported by the physician, categorized as follows:

    • Completely adherent
    • Mostly adherent
    • Somewhat adherent
    • A little adherent
    • Not at all adherent
    • Too early in patient's regimen to tell
    • Don't know

  6. Number and Percentage of Patients by Physician-reported Change in Patient Condition Since Initiation of Current MS Treatment

    Time frame: 1 Day

    Change in condition, as reported by the physician, categorized as follows:

    • Very much improved
    • Much improved
    • A little bit improved
    • No change
    • A little bit worse
    • Much worse
    • Very much worse

Secondary outcomes

  1. Number and Percentage of Patients by Factors That Influence How the Patient Rates Current Medication Compared to Previous Medication

    Time frame: 1 Day

    Factors influencing how patients rate medication include:

    • Frequency of relapses
    • Impact on symptoms during relapses
    • MS progression
    • Convenience (impact on daily routine)
    • Side effects
    • Route of administration
    • Frequency of administration
    • Impact on quality of life (e.g. liveliness, social functioning, perceived wellbeing)
    • No change / No previous medication for MS taken
    • Don't know

  2. Number and Percentage of Patients by Physician-reported Reason for Current MS Treatment Choice

    Time frame: 1 Day

  3. Number and Percentage of Patients by Physician-reported Top 5 Reasons for Current MS Treatment Choice

    Time frame: 1 Day

  4. Number and Percentage of Patients by Physician-reported Main Areas of Improvement for the Patient's Current MS Treatment

    Time frame: 1 Day

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Study Investigating Drivers of Physician and Patient Satisfaction Towards Treatment

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 1, 2026
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.